Bio-Rad Laboratories, Inc. (BIO) Earnings History
Annual and quarterly earnings data from 1989 to 2025
Loading earnings history...
BIO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BIO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 52.0% | 10.5% | 29.4% |
| 2024 | 53.7% | 10.5% | -71.9% |
| 2023 | 53.4% | 12.6% | -23.9% |
| 2022 | 55.9% | 17.2% | -129.5% |
| 2021 | 56.1% | 17.1% | 145.6% |
Download Data
Export BIO earnings history in CSV or JSON format
Free sign-in required to download data
Bio-Rad Laboratories, Inc. (BIO) Earnings Overview
As of May 6, 2026, Bio-Rad Laboratories, Inc. (BIO) reported trailing twelve-month net income of $169M, reflecting +142.6% year-over-year growth. The company earned $6.26 per diluted share over the past four quarters, with a net profit margin of 29.4%.
Looking at the long-term picture, BIO's 5-year EPS compound annual growth rate (CAGR) stands at -26.1%, signaling declining earnings. The company achieved its highest annual net income of $4.25B in fiscal 2021.
Bio-Rad Laboratories, Inc. maintains industry-leading profitability with a gross margin of 52.0%, operating margin of 10.5%, and net margin of 29.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including TMO ($6.86B net income, 15.1% margin), DHR ($3.69B net income, 14.7% margin), BRKR (-$26M net income, -0.3% margin), BIO has outperformed on profitability metrics. Compare BIO vs TMO →
BIO Earnings vs Peers
Earnings metrics vs comparable public companies
BIO Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $760M | +141.2% | $271M | $27.87 | 29.4% | 10.5% |
| 2024 | -$1.84B | -189.4% | $269M | $-65.36 | -71.9% | 10.5% |
| 2023 | -$637M | +82.4% | $338M | $-21.82 | -23.9% | 12.6% |
| 2022 | -$3.63B | -185.3% | $483M | $-121.79 | -129.5% | 17.2% |
| 2021 | $4.25B | +11.5% | $500M | $140.83 | 145.6% | 17.1% |
| 2020 | $3.81B | +116.9% | $421M | $126.20 | 149.8% | 16.6% |
| 2019 | $1.76B | +387.2% | $230M | $58.27 | 76.1% | 9.9% |
| 2018 | $361M | +214.6% | -$109M | $11.94 | 15.8% | -4.7% |
| 2017 | $115M | +308.0% | $117M | $4.07 | 5.3% | 5.4% |
| 2016 | $28M | -75.1% | $53M | $0.88 | 1.4% | 2.6% |
See BIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIO — Frequently Asked Questions
Quick answers to the most common questions about buying BIO stock.
Is BIO growing earnings?
BIO EPS is $6.26, with earnings growth accelerating to +142.6%. This exceeds the 5-year CAGR of -26.1%. TTM net income reached $169M.
What are BIO's profit margins?
Bio-Rad Laboratories, Inc. net margin is +29.4%, with operating margin at +10.5%. Above-average margins indicate pricing power.
How consistent are BIO's earnings?
BIO earnings data spans 1989-2025. The accelerating earnings trend is +142.6% YoY. Historical data enables comparison across business cycles.